A detailed history of Values First Advisors, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Values First Advisors, Inc. holds 17,892 shares of EXEL stock, worth $605,107. This represents 0.25% of its overall portfolio holdings.

Number of Shares
17,892
Previous 18,160 1.48%
Holding current value
$605,107
Previous $408,000 13.73%
% of portfolio
0.25%
Previous 0.25%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$21.96 - $27.6 $5,885 - $7,396
-268 Reduced 1.48%
17,892 $464,000
Q2 2024

Jul 19, 2024

SELL
$20.34 - $23.73 $813 - $949
-40 Reduced 0.22%
18,160 $408,000
Q1 2024

Apr 23, 2024

BUY
$20.17 - $23.93 $23,558 - $27,950
1,168 Added 6.86%
18,200 $431,000
Q4 2023

Jan 18, 2024

BUY
$19.25 - $24.13 $23,234 - $29,124
1,207 Added 7.63%
17,032 $408,000
Q3 2023

Nov 08, 2023

SELL
$19.04 - $22.74 $2,170 - $2,592
-114 Reduced 0.72%
15,825 $345,000
Q2 2023

Aug 02, 2023

BUY
$18.17 - $20.48 $6,359 - $7,168
350 Added 2.25%
15,939 $304,000
Q1 2023

May 15, 2023

BUY
$16.3 - $19.41 $7,237 - $8,618
444 Added 2.93%
15,589 $302,000
Q4 2022

Jan 20, 2023

SELL
$14.96 - $17.39 $1,615 - $1,878
-108 Reduced 0.71%
15,145 $0
Q3 2022

Dec 02, 2022

BUY
$15.68 - $22.27 $7,730 - $10,979
493 Added 3.34%
15,253 $239,000
Q2 2022

Jul 20, 2022

SELL
$17.44 - $23.16 $17,422 - $23,136
-999 Reduced 6.34%
14,760 $307,000
Q1 2022

May 03, 2022

BUY
$17.03 - $22.67 $22,837 - $30,400
1,341 Added 9.3%
15,759 $357,000
Q4 2021

Mar 10, 2022

BUY
$15.84 - $21.88 $228,381 - $315,465
14,418 New
14,418 $264,000
Q3 2021

Nov 15, 2022

BUY
$16.3 - $21.14 $17,571 - $22,788
1,078 Added 7.3%
15,838 $335,000
Q2 2021

Nov 15, 2022

SELL
$17.95 - $25.56 $5,761 - $8,204
-321 Reduced 2.05%
15,321 $279,000
Q1 2021

Nov 15, 2022

BUY
$20.53 - $25.22 $18,107 - $22,244
882 Added 5.98%
15,642 $353,000
Q4 2020

Nov 15, 2022

SELL
$18.39 - $24.8 $11,585 - $15,624
-630 Reduced 3.96%
15,275 $307,000
Q3 2020

Nov 15, 2022

BUY
$20.67 - $26.94 $17,073 - $22,252
826 Added 5.48%
15,905 $389,000
Q2 2020

Nov 15, 2022

BUY
$16.46 - $27.42 $11,735 - $19,550
713 Added 4.96%
15,079 $358,000
Q1 2020

Jan 09, 2023

BUY
$14.46 - $21.8 $2,602 - $3,924
180 Added 1.18%
15,433 $266 Million
Q4 2019

Nov 15, 2022

SELL
$15.15 - $18.89 $5,969 - $7,442
-394 Reduced 2.67%
14,366 $253,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.9B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Values First Advisors, Inc. Portfolio

Follow Values First Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Values First Advisors, Inc. with notifications on news.